A new study found that drinking coconut water every day might lead to clinical remission for people with mild to moderate ...

Biologics treat moderate-to-severe ulcerative colitis. They target and inhibit specific proteins involved in the body's inflammatory process. Biologic medication is delivered via subcutaneous ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

for induction treatment of moderate-to-severe ulcerative colitis (UC), with patients who failed on immunomodulators, anti-TNFα, vedolizumab or corticosteroids. The topline results indicate that ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Crohn's disease and ulcerative colitis are idiopathic, chronic, relapsing, inflammatory conditions that are immunologically mediated. Although their exact etiologies remain uncertain, results from ...

Oral sphingosine 1-phosphate (S1P) 1 and 5 receptor agonist Zeposia (ozanimod) achieved all its targets in the True North trial involving adults with moderate-to-severe ulcerative colitis ...

Background and Aims: Both clinical outcomes and factors predictive for poor response after an initial course of corticosteroids have not yet been well established in the treatment of moderate to ...

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the intestinal tract, when compared to placebo.

but mostly mild or moderate; no serious infectious complications occurred. Visilizumab might, therefore, benefit patients with steroid-refractory ulcerative colitis and deserves further evaluation.